Exploratory toxicology plays a critical role in successful neuroscience drug discovery. By identifying neurotoxicity, cardiotoxicity, off-target effects, and brain penetration early, researchers can make informed decisions, reduce late-stage failures, and accelerate timelines to the clinic.
Using advanced human-relevant in vitro models, high-throughput screening platforms, in vivo imaging, and microdialysis, we generate predictive data that builds confidence in small-molecule candidates. Our integrated, flexible approach supports standalone studies or full discovery pipelines—helping you advance safer, more effective CNS therapies while reducing risk, cost, and unnecessary animal use.
Designed for decision‑making – Studies aligned to your key endpoints, not just speed.
Flexible & scalable – Standalone studies or fully integrated discovery pipelines.
Move beyond mono‑culture. Our multi‑cell human iPSC‑derived models (neurons, microglia, astrocytes, oligodendrocytes) provide a more realistic assessment of neurotoxicity.
Key Benefits
Early prediction of neurotoxic effects
Human‑relevant biomarkers (e.g., Neurofilament Light – NfL)
Faster selection of the right lead candidate
“This content is brought to you by Charles River Laboratories, a global leader in preclinical and early-stage drug development services. Drawing on deep scientific expertise, advanced technologies, and industry-leading models, Charles River helps pharmaceutical and biotechnology organizations accelerate research, improve decision-making, and deliver innovative therapies to patients faster.”
Charles River Laboratories will use the data provided hereunder in accordance with the Privacy Statement.